FDA Approves Erdafitinib for Metastatic Urothelial Carcinoma

Erdafitinib (Balversa™, Janssen Pharmaceutical Companies) was recently granted FDA approval for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Erdafitinib targets genetic alterations that occur in FGFRs, which regulate important biological processes, including cell g...
Continue reading

Eliminating Cervical Cancer Worldwide: An Interview With Karen Canfell, DPhil

Cervical cancer is the fourth most common cancer in women globally, yet because it most often results from specific strains of the human papillomavirus (HPV) for which a vaccine is now available, it is becoming largely preventable. Addressing a call from World Health Organization (WHO) to eliminate cervical cancer as a public health problem, a team of researchers led by cancer epidemiologist Karen Canfell, DPhil, investigated whether it would be possible to wipe out this disease worldwide by the...
Continue reading

Advanced Renal-Cell Carcinoma: Potential First-Line Treatment

​ A phase 3 clinical trial has found that in previously untreated patients with advanced renal-cell carcinoma (RCC), avelumab plus axitinib improves progression-free survival and objective response compared with sunitinib. Sunitinib is an antiangiogenic drug, meaning that it prevents tumors from growing their own blood vessels. It is considered standard of care as a first-line therapy for patients with advanced RCC. However, many patients either have inherent resistance to antiangiogenic drugs o...
Continue reading

CK2 Inhibitor Disrupts Cancer’s Circadian Rhythm

Circadian rhythm is an important internal biological clock in charge of daily physiological processes. It regulates the sleep/wake cycle, body temperature, hormone secretion, and energy metabolism. Cells in the human body are dictated by their own circadian rhythm. According to a new study published in Science Advances , manipulating cancerous cells' circadian rhythm could potentially harm or kill malignancies by stunting their growth. In this study, researchers from the University of Southern C...
Continue reading

New Protein Mimics Interleukin 2 Sans Side Effects

Researchers have used a computer program to design a protein that mimics the action of interleukin 2 (IL-2) and interleukin 15 (IL-15) without the toxic side effects. Interleukin 2 (IL-2), a cytokine that regulates the activities of the immune system's white blood cells, is a powerful anti-cancer drug used to treat metastatic melanoma and renal cell carcinoma. However, its toxic side effects, such as impairment of kidney function, have limited its use as a cancer-fighting agent. "People have tri...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.